Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Respiratory Microbiota | Research

Aspirin inhibits rotavirus replication and alters rat gut microbial composition

Authors: Wei Zhao, ZhouPing Li, Mei Ling Yu, Yang Liu, Chang Cheng Liu, Xue Jiao Jia, Meng Qi Liu, Yong Gang Li

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

Aspirin is widely used to treat various clinical symptoms. Evidence suggests that aspirin has antiviral properties, but little is known about its specific effect against rotavirus.

Methods

MA104, Caco-2, and CV-1 cells were infected with rotavirus, and aspirin was added after 12 h. Viral mRNA and titer levels were measured by qRT-PCR and immunofluorescence assays. For in vivo validation, forty specific-pathogen-free SD rats were randomly divided into oral aspirin (ASP) groups and control (NC) groups. 16 S rRNA gene sequencing was performed to identify gut microbiota. After 6 months of continuous ASP/NC administration, the rats were infected with rotavirus. Fecal samples were collected over a 30-day time course, and viral levels were quantified. Proinflammatory cytokines/chemokine levels were measured by ELISA.

Results

Aspirin inhibited rotavirus infection in cell lines and in rats. The effects of aspirin on viral replication were associated with the alteration of gut microbiota composition by aspirin, including increased abundance of Firmicutes and decreased abundance of Bacteroidetes after aspirin treatment. Mechanistically, aspirin reduced IL-2 and IL-10 levels, and increased IRF-1 and COX-2 levels. Aspirin blocked rotavirus replication in vitro and in vivo, which might be related to effects on IRF-1, COX-2, chemokines, and gut microbial composition.

Conclusion

These results indicate that long-term oral aspirin administration reduces rotavirus infection. Intestinal virus infection may be suppressed in elderly patients who take aspirin for a long time. The change of their Gut microbiota may lead to functional disorder of the intestinal tract, which may provide some reference for clinical adjuvant probiotics treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jayaram H, Estes MK, Prasad BV. Emerging themes in rotavirus cell entry, genome organization, transcription and replication. Virus Res. 2004;101(1):67–81.PubMed Jayaram H, Estes MK, Prasad BV. Emerging themes in rotavirus cell entry, genome organization, transcription and replication. Virus Res. 2004;101(1):67–81.PubMed
2.
go back to reference Navarro A, Williamson L, Angel M, et al. Chapter 2.3 - Rotavirus Replication and Reverse Genetics. In: Svensson L, Desselberger U, Greenberg HB, et al. editors. Viral gastroenteritis. Boston: Academic Press; 2016. pp. 121–43. Navarro A, Williamson L, Angel M, et al. Chapter 2.3 - Rotavirus Replication and Reverse Genetics. In: Svensson L, Desselberger U, Greenberg HB, et al. editors. Viral gastroenteritis. Boston: Academic Press; 2016. pp. 121–43.
3.
go back to reference Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Therapy. 2005;22(5):476–87. Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Therapy. 2005;22(5):476–87.
4.
go back to reference Tate JE, Burton AH, Boschi-Pinto C, et al. Global, Regional, and National estimates of Rotavirus Mortality in Children < 5 years of Age, 2000–2013. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2016;62(Suppl 2):96–s105. Tate JE, Burton AH, Boschi-Pinto C, et al. Global, Regional, and National estimates of Rotavirus Mortality in Children < 5 years of Age, 2000–2013. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2016;62(Suppl 2):96–s105.
5.
go back to reference Crawford SE, Ramani S, Tate JE, et al. Rotavirus infection. Nat Reviews Disease Primers. 2017;3:17083.PubMed Crawford SE, Ramani S, Tate JE, et al. Rotavirus infection. Nat Reviews Disease Primers. 2017;3:17083.PubMed
6.
go back to reference Mayanskiy NA, Mayanskiy AN, Kulichenko TV. [Rotavirus infection: epidemiology, pathology, vaccination]. Vestn Ross Akad Med Nauk. 2015;1:47–55. Mayanskiy NA, Mayanskiy AN, Kulichenko TV. [Rotavirus infection: epidemiology, pathology, vaccination]. Vestn Ross Akad Med Nauk. 2015;1:47–55.
7.
go back to reference Markkula J, Hemming-Harlo M, Salminen MT, et al. Rotavirus epidemiology 5–6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly. Infect Dis (London England). 2017;49(5):388–95. Markkula J, Hemming-Harlo M, Salminen MT, et al. Rotavirus epidemiology 5–6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly. Infect Dis (London England). 2017;49(5):388–95.
8.
go back to reference McCarthy DM. Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. Best Pract Res Clin Gastroenterol. 2012;26(2):101–12.PubMedPubMedCentral McCarthy DM. Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. Best Pract Res Clin Gastroenterol. 2012;26(2):101–12.PubMedPubMedCentral
9.
go back to reference Bachert C, Chuchalin AG, Eisebitt R, et al. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther. 2005;27(7):993–1003.PubMed Bachert C, Chuchalin AG, Eisebitt R, et al. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study. Clin Ther. 2005;27(7):993–1003.PubMed
10.
go back to reference Morris T, Stables M, Hobbs A, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol (Baltimore Md: 1950). 2009;183(3):2089–96. Morris T, Stables M, Hobbs A, et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol (Baltimore Md: 1950). 2009;183(3):2089–96.
11.
go back to reference Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol. 2019;113:1–8.PubMed Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol. 2019;113:1–8.PubMed
12.
go back to reference Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800–6.PubMed Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346(23):1800–6.PubMed
13.
go back to reference Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014;12(3–4):147–54.PubMedPubMedCentral Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014;12(3–4):147–54.PubMedPubMedCentral
14.
go back to reference Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922–32.PubMed Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922–32.PubMed
15.
go back to reference Gracey M, Phadke MA, Burke V, et al. Aspirin in acute gastroenteritis: a clinical and microbiological study. J Pediatr Gastroenterol Nutr. 1984;3(5):692–5.PubMed Gracey M, Phadke MA, Burke V, et al. Aspirin in acute gastroenteritis: a clinical and microbiological study. J Pediatr Gastroenterol Nutr. 1984;3(5):692–5.PubMed
16.
go back to reference Huang RT, Dietsch E. Anti-influenza viral activity of aspirin in cell culture. N Engl J Med. 1988;319(12):797.PubMed Huang RT, Dietsch E. Anti-influenza viral activity of aspirin in cell culture. N Engl J Med. 1988;319(12):797.PubMed
17.
go back to reference Mazur I, Wurzer WJ, Ehrhardt C, et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 2007;9(7):1683–94.PubMed Mazur I, Wurzer WJ, Ehrhardt C, et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 2007;9(7):1683–94.PubMed
18.
go back to reference Glatthaar-Saalmüller B, Mair KH, Saalmüller A. Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. Influenza Other Respir Viruses. 2017;11(1):85–92.PubMed Glatthaar-Saalmüller B, Mair KH, Saalmüller A. Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. Influenza Other Respir Viruses. 2017;11(1):85–92.PubMed
19.
go back to reference Primache V, Binda S, De Benedittis G, et al. In vitro activity of acetylsalicylic acid on replication of varicella-zoster virus. new Microbiol. 1998;21(4):397–401.PubMed Primache V, Binda S, De Benedittis G, et al. In vitro activity of acetylsalicylic acid on replication of varicella-zoster virus. new Microbiol. 1998;21(4):397–401.PubMed
20.
go back to reference Speir E, Yu ZX, Ferrans VJ, et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circul Res. 1998;83(2):210–6. Speir E, Yu ZX, Ferrans VJ, et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circul Res. 1998;83(2):210–6.
21.
go back to reference Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J Viral Hepatitis. 2016;23(1):62–4. Yin P, Zhang L. Aspirin inhibits hepatitis C virus entry by downregulating claudin-1. J Viral Hepatitis. 2016;23(1):62–4.
22.
go back to reference Rivas-Estilla AM, Bryan-Marrugo OL, Trujillo-Murillo K, et al. Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. Am J Physiol Gastrointest Liver Physiol. 2012;302(11):G1264–1273.PubMed Rivas-Estilla AM, Bryan-Marrugo OL, Trujillo-Murillo K, et al. Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. Am J Physiol Gastrointest Liver Physiol. 2012;302(11):G1264–1273.PubMed
23.
go back to reference Liu SF, Wang H, Li ZJ, et al. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells. Eur J Pharmacol. 2008;589(1–3):8–13.PubMed Liu SF, Wang H, Li ZJ, et al. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells. Eur J Pharmacol. 2008;589(1–3):8–13.PubMed
24.
go back to reference Bitko V, Velazquez A, Yang L, et al. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology. 1997;232(2):369–78.PubMed Bitko V, Velazquez A, Yang L, et al. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology. 1997;232(2):369–78.PubMed
25.
go back to reference Chen CJ, Raung SL, Kuo MD, et al. Suppression of japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol. 2002;83(Pt 8):1897–905.PubMed Chen CJ, Raung SL, Kuo MD, et al. Suppression of japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol. 2002;83(Pt 8):1897–905.PubMed
26.
go back to reference Trujillo-Murillo K, Rincón-Sánchez AR, Martínez-Rodríguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology (Baltimore MD). 2008;47(5):1462–72.PubMed Trujillo-Murillo K, Rincón-Sánchez AR, Martínez-Rodríguez H, et al. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology (Baltimore MD). 2008;47(5):1462–72.PubMed
27.
go back to reference Pereira CF, Paridaen JT, Rutten K, et al. Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication. Antiviral Res. 2003;58(3):253–63.PubMed Pereira CF, Paridaen JT, Rutten K, et al. Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication. Antiviral Res. 2003;58(3):253–63.PubMed
28.
go back to reference Falcinelli E, Francisci D, Schiaroli E, et al. Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. Int J Cardiol. 2018;263:118–24.PubMed Falcinelli E, Francisci D, Schiaroli E, et al. Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients. Int J Cardiol. 2018;263:118–24.PubMed
29.
go back to reference Rizk JG, Lavie CJ, Gupta A. Low-dose aspirin for early COVID-19: does the early bird catch the worm? Expert Opin Investig Drugs. 2021;30(8):785–8.PubMed Rizk JG, Lavie CJ, Gupta A. Low-dose aspirin for early COVID-19: does the early bird catch the worm? Expert Opin Investig Drugs. 2021;30(8):785–8.PubMed
30.
go back to reference Wijaya I, Andhika R, Huang I, et al. The effects of aspirin on the outcome of COVID-19: a systematic review and meta-analysis. Clin Epidemiol Global Health. 2021;12:100883. Wijaya I, Andhika R, Huang I, et al. The effects of aspirin on the outcome of COVID-19: a systematic review and meta-analysis. Clin Epidemiol Global Health. 2021;12:100883.
31.
go back to reference Rossen JW, Bouma J, Raatgeep RH, et al. Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J Virol. 2004;78(18):9721–30.PubMedPubMedCentral Rossen JW, Bouma J, Raatgeep RH, et al. Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J Virol. 2004;78(18):9721–30.PubMedPubMedCentral
32.
go back to reference Komoto S, Fukuda S, Ide T, et al. Generation of recombinant Rotaviruses expressing fluorescent proteins by using an optimized Reverse Genetics System. J Virol. 2018;92:13. Komoto S, Fukuda S, Ide T, et al. Generation of recombinant Rotaviruses expressing fluorescent proteins by using an optimized Reverse Genetics System. J Virol. 2018;92:13.
33.
go back to reference Zhao W, Yu ML, Tao X, et al. Analysis of the intestinal microbial community altered during rotavirus infection in suckling mice. Virol J. 2021;18(1):254.PubMedPubMedCentral Zhao W, Yu ML, Tao X, et al. Analysis of the intestinal microbial community altered during rotavirus infection in suckling mice. Virol J. 2021;18(1):254.PubMedPubMedCentral
34.
go back to reference Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228–35.PubMedPubMedCentral Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228–35.PubMedPubMedCentral
35.
go back to reference Schloss PD, Handelsman J, Introducing DOTUR. A computer program for defining operational taxonomic units and estimating species richness. Appl Environ Microbiol. 2005;71(3):1501–6.PubMedPubMedCentral Schloss PD, Handelsman J, Introducing DOTUR. A computer program for defining operational taxonomic units and estimating species richness. Appl Environ Microbiol. 2005;71(3):1501–6.PubMedPubMedCentral
36.
go back to reference Lozupone CA, Hamady M, Kelley ST, et al. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol. 2007;73(5):1576–85.PubMedPubMedCentral Lozupone CA, Hamady M, Kelley ST, et al. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol. 2007;73(5):1576–85.PubMedPubMedCentral
37.
go back to reference Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–21.PubMedPubMedCentral Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814–21.PubMedPubMedCentral
38.
39.
go back to reference Parks DH, Tyson GW, Hugenholtz P, et al. STAMP: statistical analysis of taxonomic and functional profiles. Bioinf (Oxford England). 2014;30(21):3123–4. Parks DH, Tyson GW, Hugenholtz P, et al. STAMP: statistical analysis of taxonomic and functional profiles. Bioinf (Oxford England). 2014;30(21):3123–4.
40.
go back to reference Iaconis G, Jackson B, Childs K et al. Rotavirus NSP1 inhibits type I and type III Interferon induction. Viruses 2021; 13 (4). Iaconis G, Jackson B, Childs K et al. Rotavirus NSP1 inhibits type I and type III Interferon induction. Viruses 2021; 13 (4).
41.
go back to reference Yamashiro Y, Shimizu T, Oguchi S, et al. Prostaglandins in the plasma and stool of children with rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1989;9(3):322–7.PubMed Yamashiro Y, Shimizu T, Oguchi S, et al. Prostaglandins in the plasma and stool of children with rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr. 1989;9(3):322–7.PubMed
42.
go back to reference Rollo EE, Kumar KP, Reich NC, et al. The epithelial cell response to rotavirus infection. J Immunol (Baltimore Md: 1950). 1999;163(8):4442–52. Rollo EE, Kumar KP, Reich NC, et al. The epithelial cell response to rotavirus infection. J Immunol (Baltimore Md: 1950). 1999;163(8):4442–52.
43.
go back to reference Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Reviews Clin Oncol. 2012;9(5):259–67. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Reviews Clin Oncol. 2012;9(5):259–67.
44.
go back to reference Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet (London England). 2019;393(10186):2155–67.PubMed Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet (London England). 2019;393(10186):2155–67.PubMed
45.
go back to reference Murphy E, Curneen JMG, McEvoy JW. Aspirin in the modern era of Cardiovascular Disease Prevention. Methodist Debakey Cardiovasc J. 2021;17(4):36–47.PubMedPubMedCentral Murphy E, Curneen JMG, McEvoy JW. Aspirin in the modern era of Cardiovascular Disease Prevention. Methodist Debakey Cardiovasc J. 2021;17(4):36–47.PubMedPubMedCentral
46.
go back to reference Di Bella S, Luzzati R, Principe L et al. Aspirin and Infection: A Narrative Review Biomedicines 2022; 10 (2). Di Bella S, Luzzati R, Principe L et al. Aspirin and Infection: A Narrative Review Biomedicines 2022; 10 (2).
47.
go back to reference Soriano-Brücher H, Avendaño P, O’Ryan M, et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics. 1991;87(1):18–27.PubMed Soriano-Brücher H, Avendaño P, O’Ryan M, et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study. Pediatrics. 1991;87(1):18–27.PubMed
48.
go back to reference Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275(20):14838–45.PubMed Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275(20):14838–45.PubMed
49.
go back to reference Steer SA, Corbett JA. The role and regulation of COX-2 during viral infection. Viral Immunol. 2003;16(4):447–60.PubMed Steer SA, Corbett JA. The role and regulation of COX-2 during viral infection. Viral Immunol. 2003;16(4):447–60.PubMed
50.
go back to reference Radi ZA, Meyerholz DK, Ackermann MR. Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection. Viral Immunol. 2010;23(1):43–8.PubMedPubMedCentral Radi ZA, Meyerholz DK, Ackermann MR. Pulmonary cyclooxygenase-1 (COX-1) and COX-2 cellular expression and distribution after respiratory syncytial virus and parainfluenza virus infection. Viral Immunol. 2010;23(1):43–8.PubMedPubMedCentral
51.
go back to reference Brooks DG et al. Trifilo Mj Fau - Edelmann KH, Edelmann Kh Fau - Teyton L. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; Nov;12(11): 1301–1309. Brooks DG et al. Trifilo Mj Fau - Edelmann KH, Edelmann Kh Fau - Teyton L. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006; Nov;12(11): 1301–1309.
52.
go back to reference Ouyang W, Rutz S, Fau - Crellin NK, Crellin Nk Fau -, Valdez PA, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109.PubMed Ouyang W, Rutz S, Fau - Crellin NK, Crellin Nk Fau -, Valdez PA, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109.PubMed
53.
go back to reference Abbas AA-O, Trotta E et al. D RS. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol 2018; 2018;3(25):eaat1482. Abbas AA-O, Trotta E et al. D RS. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol 2018; 2018;3(25):eaat1482.
54.
go back to reference Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nat 2012; Jun 13;486(7402):207–14. Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nat 2012; Jun 13;486(7402):207–14.
55.
go back to reference Kim IS, Yoo DH, Jung IH et al. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem Pharmacol 2016; Dec 15;122: 72–9. Kim IS, Yoo DH, Jung IH et al. Reduced metabolic activity of gut microbiota by antibiotics can potentiate the antithrombotic effect of aspirin. Biochem Pharmacol 2016; Dec 15;122: 72–9.
56.
go back to reference Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nat 2016; Jul 7;535(7610):85–93. Bäumler AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nat 2016; Jul 7;535(7610):85–93.
Metadata
Title
Aspirin inhibits rotavirus replication and alters rat gut microbial composition
Authors
Wei Zhao
ZhouPing Li
Mei Ling Yu
Yang Liu
Chang Cheng Liu
Xue Jiao Jia
Meng Qi Liu
Yong Gang Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02199-5

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.